Integration of single-cell RNA sequencing and spatial transcriptomics to reveal the glioblastoma heterogeneity

F1000Res. 2022 Oct 17:11:1180. doi: 10.12688/f1000research.126243.2. eCollection 2022.

Abstract

Glioblastoma (GBM), a deadly brain tumor, is still one of a few lasting challenges of contemporary oncology. Current therapies fail to significantly improve patient survival due to GBM tremendous genetic, transcriptomic, immunological, and sex-dependent heterogeneity. Over the years, clinical differences between males and females were characterized. For instance, higher incidence of GBM in males or distinct responses to cancer chemotherapy and immunotherapy between males and females have been noted. Despite the introduction of single-cell RNA sequencing and spatial transcriptomics, these differences were not further investigated as studies were focused only on revealing the general picture of GBM heterogeneity. Hence, in this mini-review, we summarized the current state of knowledge on GBM heterogeneity revealed by single-cell RNA sequencing and spatial transcriptomics with regard to genetics, immunology, and sex-dependent differences. Additionally, we highlighted future research directions which would fill the gap of knowledge on the impact of patient's sex on the disease outcome.

Keywords: glioblastoma; heterogeneity; immunology; sex; single-cell RNA sequencing; spatial transcriptomics.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain Neoplasms* / genetics
  • Brain Neoplasms* / pathology
  • Brain Neoplasms* / therapy
  • Female
  • Gene Expression Profiling
  • Glioblastoma* / genetics
  • Humans
  • Male
  • Sequence Analysis, RNA
  • Transcriptome

Grants and funding

This research was supported in part by National Science Centre, Poland [Grant Number: 2021/41/N/NZ4/02317 and 2017/27/B/NZ2/02827] and the Foundation for Polish Science under the International Research Agendas Program financed from the Smart Growth Operational Program 2014–2020 (Grant Agreement No. MAB/2018/6).